The University of Chicago Header Logo

Bruce Brockstein

Concepts (281)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Head and Neck Neoplasms
44
2023
1062
4.210
Why?
Carcinoma, Squamous Cell
26
2018
1095
2.160
Why?
Antineoplastic Combined Chemotherapy Protocols
29
2021
2550
1.630
Why?
B7-H1 Antigen
2
2023
272
1.340
Why?
Antineoplastic Agents
16
2019
2410
1.280
Why?
Thrombocytopenia
1
2020
187
0.680
Why?
Pharmaceutical Preparations
1
2020
91
0.680
Why?
Sarcoma
5
2015
220
0.650
Why?
Biomarkers, Tumor
5
2023
1532
0.600
Why?
ErbB Receptors
4
2016
500
0.590
Why?
Biopsy
2
2019
1180
0.550
Why?
Bone Neoplasms
3
2013
328
0.440
Why?
Taxoids
5
2014
130
0.430
Why?
Combined Modality Therapy
18
2010
1708
0.420
Why?
Epidermal Growth Factor
2
2012
117
0.410
Why?
Paclitaxel
11
2008
478
0.410
Why?
Humans
73
2023
88852
0.400
Why?
Fluorouracil
14
2014
561
0.400
Why?
Antibodies, Monoclonal, Humanized
7
2021
967
0.370
Why?
Aged
40
2021
19019
0.350
Why?
Survival Rate
13
2019
1881
0.340
Why?
Neoplasms
7
2023
3020
0.330
Why?
Granulocyte Colony-Stimulating Factor
3
2003
166
0.330
Why?
Radiotherapy
1
2010
331
0.320
Why?
Middle Aged
39
2021
25787
0.300
Why?
Male
46
2021
42135
0.280
Why?
Osteosarcoma
2
2004
160
0.280
Why?
Red-Cell Aplasia, Pure
1
2006
5
0.280
Why?
Hydroxyurea
12
2014
239
0.280
Why?
Aged, 80 and over
18
2021
6758
0.280
Why?
Paraneoplastic Syndromes
1
2006
16
0.270
Why?
Antibodies, Monoclonal
5
2015
1399
0.270
Why?
Carcinoma, Basal Cell
1
2006
61
0.270
Why?
Prognosis
12
2019
3757
0.260
Why?
Adult
34
2021
26439
0.260
Why?
Female
45
2021
45899
0.250
Why?
Advance Care Planning
2
2016
43
0.250
Why?
Deglutition Disorders
3
2018
119
0.240
Why?
Treatment Outcome
16
2018
8178
0.240
Why?
Melanoma
2
2021
466
0.220
Why?
Skin Neoplasms
2
2006
578
0.220
Why?
Soft Tissue Neoplasms
1
2004
128
0.220
Why?
Hemangiosarcoma
3
2012
17
0.220
Why?
Neoplasm Recurrence, Local
8
2015
1354
0.220
Why?
Quality of Life
8
2018
1661
0.210
Why?
Quinazolines
3
2010
221
0.210
Why?
Cyclin-Dependent Kinase Inhibitor p16
1
2023
112
0.210
Why?
Disease-Free Survival
11
2013
1213
0.210
Why?
Molecular Targeted Therapy
2
2016
285
0.200
Why?
Cetuximab
3
2012
117
0.200
Why?
Lymphatic Metastasis
1
2023
502
0.190
Why?
Lactones
1
2001
27
0.190
Why?
Ipilimumab
1
2021
61
0.190
Why?
Breast Neoplasms
4
2001
2991
0.190
Why?
Venous Thromboembolism
1
2023
159
0.180
Why?
Spouses
1
2020
32
0.180
Why?
Trastuzumab
1
2020
71
0.180
Why?
Thrombosis
1
2023
302
0.180
Why?
Radiation-Sensitizing Agents
1
2000
96
0.170
Why?
Alanine
1
2019
83
0.170
Why?
Antineoplastic Agents, Phytogenic
2
2003
277
0.170
Why?
Hematopoietic Stem Cell Transplantation
2
1996
885
0.170
Why?
Triazines
1
2019
53
0.170
Why?
Antibodies
1
2020
353
0.160
Why?
Withholding Treatment
1
2019
117
0.160
Why?
Medical Oncology
3
2016
379
0.160
Why?
Pharyngeal Neoplasms
1
2018
15
0.160
Why?
Neoplasm Staging
12
2015
1989
0.160
Why?
Lymphoma
1
2000
264
0.160
Why?
Neoplasms, Second Primary
3
2013
259
0.160
Why?
Receptor, IGF Type 1
2
2015
45
0.150
Why?
Immunohistochemistry
2
2019
1796
0.150
Why?
Lung Diseases
1
2000
269
0.150
Why?
Heart Diseases
1
2000
298
0.150
Why?
Communication
1
2020
457
0.140
Why?
Intubation, Intratracheal
1
2018
147
0.140
Why?
Reproducibility of Results
1
2023
2750
0.140
Why?
Neoplasm Metastasis
4
2009
1107
0.140
Why?
Terminal Care
2
2016
137
0.140
Why?
Drug Therapy
1
2016
70
0.140
Why?
Neoplasms, Germ Cell and Embryonal
1
2016
48
0.130
Why?
Drug Design
1
2016
124
0.130
Why?
Pharyngectomy
1
2015
8
0.130
Why?
Drug Administration Schedule
7
2010
894
0.130
Why?
Testicular Neoplasms
1
2016
113
0.130
Why?
Programmed Cell Death 1 Receptor
1
2016
169
0.120
Why?
Patient Care Planning
1
2015
83
0.120
Why?
Bone Marrow
1
1996
445
0.120
Why?
Clinical Trials, Phase II as Topic
3
2004
172
0.120
Why?
Camptothecin
2
2009
193
0.120
Why?
Outpatients
1
2014
100
0.120
Why?
Antineoplastic Agents, Immunological
1
2016
195
0.120
Why?
Self Care
1
2015
164
0.120
Why?
Health Personnel
1
2016
210
0.110
Why?
Clinical Trials as Topic
4
2016
1146
0.110
Why?
Health Promotion
1
2015
163
0.110
Why?
Lung Neoplasms
1
2006
2344
0.110
Why?
Oropharyngeal Neoplasms
1
2015
132
0.110
Why?
Incidence
5
2008
1591
0.110
Why?
Randomized Controlled Trials as Topic
2
2011
832
0.110
Why?
Patient-Centered Care
1
2015
207
0.110
Why?
Follow-Up Studies
5
2019
3649
0.110
Why?
Spinal Cord
1
1994
255
0.110
Why?
Carboplatin
4
2008
304
0.110
Why?
Hemangioendothelioma, Epithelioid
1
2012
9
0.110
Why?
Drug Resistance, Neoplasm
1
2016
615
0.100
Why?
Radiotherapy Dosage
5
2006
470
0.100
Why?
Proto-Oncogene Proteins B-raf
1
2013
146
0.100
Why?
Patient Education as Topic
1
2015
357
0.100
Why?
Sirolimus
1
2013
170
0.100
Why?
Risk Factors
5
2023
5448
0.100
Why?
Indoles
1
2013
312
0.100
Why?
Models, Statistical
1
2015
575
0.100
Why?
Salvage Therapy
4
2008
235
0.090
Why?
Sulfonamides
1
2013
317
0.090
Why?
Immunotherapy
1
2016
664
0.090
Why?
Methotrexate
1
2011
250
0.090
Why?
Attitude of Health Personnel
1
2016
643
0.090
Why?
Quality Improvement
1
2014
446
0.090
Why?
Surveys and Questionnaires
4
2016
2607
0.090
Why?
Developing Countries
1
2010
76
0.090
Why?
Mouth Neoplasms
1
2012
198
0.090
Why?
Remission Induction
4
2008
738
0.090
Why?
Polyethylene Glycols
1
2012
358
0.090
Why?
Leiomyoma
1
2013
200
0.080
Why?
United States
5
2010
6931
0.080
Why?
Blood Coagulation Factor Inhibitors
1
2008
4
0.080
Why?
Time Factors
4
2015
5313
0.080
Why?
Benzenesulfonates
1
2009
66
0.080
Why?
Erlotinib Hydrochloride
1
2008
90
0.080
Why?
Administration, Oral
4
2012
682
0.080
Why?
Protein Kinase Inhibitors
2
2013
602
0.080
Why?
Blood Coagulation Disorders
1
2008
66
0.070
Why?
Interdisciplinary Communication
2
2008
130
0.070
Why?
Feasibility Studies
3
2020
778
0.070
Why?
Transplantation, Autologous
2
2000
342
0.070
Why?
Cisplatin
3
2014
617
0.070
Why?
Pyridines
1
2009
315
0.070
Why?
Doxorubicin
2
2015
298
0.070
Why?
Heart Failure
1
2016
1172
0.070
Why?
Signal Transduction
1
2016
3370
0.060
Why?
Prospective Studies
2
2023
4258
0.060
Why?
Pilot Projects
2
2020
865
0.060
Why?
Recombinant Proteins
3
2003
1011
0.060
Why?
Survival Analysis
5
2012
1533
0.060
Why?
Young Adult
5
2015
6271
0.060
Why?
Postoperative Complications
1
2015
2273
0.060
Why?
Dermatofibrosarcoma
1
2004
13
0.060
Why?
Fibromatosis, Aggressive
1
2004
11
0.060
Why?
Neoplasm Invasiveness
2
2004
575
0.060
Why?
Radionuclide Imaging
1
2004
221
0.060
Why?
Rhabdomyosarcoma
1
2004
42
0.060
Why?
Chondrosarcoma
1
2004
48
0.060
Why?
Adolescent
6
2018
9201
0.060
Why?
Neck Dissection
1
2004
67
0.060
Why?
Radiation Tolerance
1
2004
173
0.060
Why?
Factor V
1
2023
10
0.060
Why?
Prothrombin
1
2023
17
0.060
Why?
Cancer Care Facilities
1
2003
29
0.060
Why?
Travel
1
2003
71
0.050
Why?
Analysis of Variance
2
2006
901
0.050
Why?
Uracil
2
1999
55
0.050
Why?
Chemotherapy, Adjuvant
4
2006
485
0.050
Why?
Vascular Neoplasms
1
2001
21
0.050
Why?
Bryostatins
1
2001
15
0.050
Why?
Macrolides
1
2001
31
0.050
Why?
Retrospective Studies
5
2018
8963
0.050
Why?
Neoplasms, Radiation-Induced
1
2001
109
0.050
Why?
Otorhinolaryngologic Neoplasms
1
2000
4
0.050
Why?
Antimetabolites, Antineoplastic
2
1999
237
0.040
Why?
Hematopoietic Stem Cell Mobilization
1
2000
50
0.040
Why?
Patient Selection
1
2003
681
0.040
Why?
Maximum Tolerated Dose
2
2015
272
0.040
Why?
Breast
1
2001
292
0.040
Why?
Cyclophosphamide
1
2000
299
0.040
Why?
Predictive Value of Tests
2
2003
1713
0.040
Why?
Bone Marrow Transplantation
1
2000
283
0.040
Why?
Social Support
1
2020
208
0.040
Why?
Oxidoreductases
1
1999
112
0.040
Why?
Mutation
2
2023
4121
0.040
Why?
Kaplan-Meier Estimate
2
2012
858
0.040
Why?
Disease Progression
3
2012
1483
0.040
Why?
Transplantation Conditioning
1
2000
374
0.040
Why?
Pyrazines
1
1998
94
0.040
Why?
Stroke Volume
1
2000
461
0.040
Why?
alpha-Fetoproteins
1
2016
43
0.030
Why?
Cell Separation
1
1996
198
0.030
Why?
Logistic Models
1
2000
1209
0.030
Why?
Smoking
1
2000
620
0.030
Why?
Vascular Endothelial Growth Factor A
2
2009
420
0.030
Why?
Transitional Care
1
2015
18
0.030
Why?
Age Factors
1
2000
1862
0.030
Why?
Patient Reported Outcome Measures
1
2016
190
0.030
Why?
DNA Mutational Analysis
1
2016
529
0.030
Why?
Cardiology
1
2016
114
0.030
Why?
Physicians, Primary Care
1
2016
105
0.030
Why?
Radiotherapy, Adjuvant
2
2006
295
0.030
Why?
Veins
1
1994
95
0.030
Why?
Documentation
1
2014
103
0.030
Why?
Cost-Benefit Analysis
1
2016
461
0.030
Why?
Ambulatory Care
1
2015
187
0.030
Why?
Survivors
1
2015
233
0.030
Why?
Recurrence
1
1996
1140
0.030
Why?
Continuity of Patient Care
1
2015
172
0.030
Why?
Induction Chemotherapy
1
2014
149
0.030
Why?
Arteries
1
1994
180
0.030
Why?
Terminology as Topic
1
1994
221
0.030
Why?
4-Nitroquinoline-1-oxide
1
2012
15
0.030
Why?
Administration, Topical
1
2012
96
0.030
Why?
Amino Acid Substitution
1
2013
338
0.030
Why?
Kidney Neoplasms
1
1998
634
0.030
Why?
Rats, Inbred F344
1
2012
154
0.030
Why?
Cyclin D1
1
2012
84
0.030
Why?
Cyclin-Dependent Kinase Inhibitor p21
1
2012
80
0.030
Why?
Mouth Mucosa
1
2012
67
0.030
Why?
Chemoprevention
1
2012
92
0.030
Why?
Mutation, Missense
1
2013
277
0.030
Why?
Chemoradiotherapy
1
2014
309
0.020
Why?
TOR Serine-Threonine Kinases
1
2013
185
0.020
Why?
Liver Neoplasms
1
1998
754
0.020
Why?
Neoplasm Grading
1
2013
372
0.020
Why?
Databases, Factual
1
2015
849
0.020
Why?
Bevacizumab
1
2012
287
0.020
Why?
Electronic Health Records
1
2014
341
0.020
Why?
Drug-Related Side Effects and Adverse Reactions
1
2013
201
0.020
Why?
Blotting, Western
1
2012
794
0.020
Why?
Down-Regulation
1
2012
519
0.020
Why?
Cross-Sectional Studies
1
2016
1698
0.020
Why?
Cell Cycle
1
2012
509
0.020
Why?
Colorectal Neoplasms
1
1998
980
0.020
Why?
T-Lymphocytes
1
2016
1222
0.020
Why?
Cell Transformation, Neoplastic
1
2012
447
0.020
Why?
Lymph Nodes
2
2004
548
0.020
Why?
Cyclooxygenase 2
1
2009
99
0.020
Why?
Cohort Studies
2
2008
2855
0.020
Why?
Niacinamide
1
2009
115
0.020
Why?
Blood Coagulation Tests
1
2008
35
0.020
Why?
Phenylurea Compounds
1
2009
114
0.020
Why?
Glucuronosyltransferase
1
2009
186
0.020
Why?
Dose-Response Relationship, Radiation
1
2008
188
0.020
Why?
Epithelial Cells
1
2012
688
0.020
Why?
Population Surveillance
1
2008
216
0.020
Why?
Animals
2
2012
27272
0.020
Why?
Cell Line, Tumor
1
2012
2549
0.020
Why?
Tomography, X-Ray Computed
1
2016
2649
0.020
Why?
Cell Proliferation
1
2012
1649
0.020
Why?
Transforming Growth Factor alpha
1
2005
50
0.020
Why?
Rats
1
2012
4039
0.020
Why?
Deglutition
1
2006
76
0.020
Why?
Multicenter Studies as Topic
1
2004
155
0.010
Why?
Biopsy, Needle
1
2004
233
0.010
Why?
Probability
1
2004
353
0.010
Why?
Filgrastim
1
2003
57
0.010
Why?
Hospitals, University
1
2003
195
0.010
Why?
Erythropoietin
1
2003
88
0.010
Why?
Bias
1
2003
131
0.010
Why?
Cause of Death
1
2004
266
0.010
Why?
Neutropenia
1
2003
216
0.010
Why?
Odds Ratio
1
2003
684
0.010
Why?
Case-Control Studies
1
2006
1849
0.010
Why?
Proportional Hazards Models
1
2003
848
0.010
Why?
Multivariate Analysis
1
2003
986
0.010
Why?
Mastectomy, Segmental
1
2001
94
0.010
Why?
Referral and Consultation
1
2003
341
0.010
Why?
Infusions, Intravenous
1
2001
434
0.010
Why?
Comorbidity
1
2004
947
0.010
Why?
Barium Sulfate
1
2000
43
0.010
Why?
Lymphedema
1
2001
77
0.010
Why?
Fluoroscopy
1
2000
122
0.010
Why?
Illinois
1
2001
472
0.010
Why?
Dihydrouracil Dehydrogenase (NADP)
1
1999
29
0.010
Why?
Tegafur
1
1998
17
0.010
Why?
Video Recording
1
2000
201
0.010
Why?
Chicago
1
2003
1423
0.010
Why?
Dose-Response Relationship, Drug
1
2003
1938
0.010
Why?
Etoposide
1
1998
198
0.010
Why?
Cell Count
1
1998
199
0.010
Why?
Skin
1
2001
581
0.010
Why?
Radiography
1
1999
809
0.010
Why?
Enzyme Inhibitors
1
1999
645
0.010
Why?
Contrast Media
1
2000
1090
0.010
Why?
Brockstein's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (281)
Explore
_
Co-Authors (42)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_
Physical Neighbors
_